Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma

International Journal of Urology

Volumn 19, Issue 11, 2012, Pages 1017-1025

  Sanders, Imke ^a   Holdenrieder, Stefan ^a   Walgenbach Brünagel, Gisela ^a   von Ruecker, Alexander ^a   Kristiansen, Glen ^a   Müller, Stefan C ^a   Ellinger, Jörg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Bladder cancer; MiRNA; Prostate cancer; Reference gene; Renal cell carcinoma

Indexed keywords

COMPLEMENTARY DNA; MICRORNA; MICRORNA 106A; MICRORNA 21; MICRORNA 39; MICRORNA LET 7A; RNU1 4 PROTEIN; RNU6 2 PROTEIN; SNORD43 PROTEIN; SNORD44 PROTEIN; SNORD48 PROTEIN; SNORD74A PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; GENETIC STABILITY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; URINARY BLADDER NEOPLASMS;

EID: 84868193269     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03082.x     Document Type: Article

References (46)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
2. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006; 6: 259-69.
3. Volinia S, Calin GA, Liu CG etal. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 2006; 103: 2257-61.
4. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-55.
5. Lawrie CH, Gal S, Dunlop HM etal. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008; 141: 672-5.
6. Mitchell PS, Parkin RK, Kroh EM etal. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 10513-18.
7. Chim SS, Shing TK, Hung EC etal. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem. 2008; 54: 482-90.
8. Hunter MP, Ismail N, Zhang X etal. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008; 3: e3694.
9. Chen X, Ba Y, Ma L etal. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18: 997-1006.
10. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010; 38: 7248-59.
11. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39: 7223-33.
12. Wotschofsky Z, Meyer HA, Jung M etal. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal. Biochem. 2011; 417: 233-41.
13. Vandesompele J, De Preter K, Pattyn F etal. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3: RESEARCH0034.
14. Wittmann J, Jack HM. Serum microRNAs as powerful cancer biomarkers. Biochim. Biophys. Acta 2010; 1806: 200-7.
15. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011; 77: 1265-16.
16. Schaefer A, Jung M, Miller K etal. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp. Mol. Med. 2010; 42: 749-58.
17. Carlsson J, Helenius G, Karlsson M etal. Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues. Cancer Genet. Cytogenet. 2010; 202: 71-5.
18. Leite KR, Tomiyama A, Reis ST etal. MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol. Oncol. 2011; doi: 10.1016/j.urolonc.2011.07.002.
19. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol. Biol. 2008; 9: 76.
20. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 2010; 10: 173.
21. Zhu HT, Dong QZ, Wang G etal. Identification of suitable reference genes for qRT-PCR analysis of circulating microRNAs in hepatitis B virus-infected patients. Mol. Biotechnol. 2012; 50: 49-56.
22. Song J, Bai Z, Han W etal. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig. Dis. Sci. 2012; 57: 897-904.
23. Silver N, Best S, Jiang J, Thein SL. Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol. Biol. 2006; 7: 33.
24. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004; 64: 5245-50.
25. Yaman AF, Kovancilar M, Dizdar Y etal. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour. Biol. 2011; 32: 583-8.
26. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011; 57: 84-91.
27. Huang Y, Dai Y, Yang J etal. Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur. J. Surg. Oncol. 2009; 35: 1119-23.
28. Chow TF, Youssef YM, Lianidou E etal. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem. 2010; 43: 150-8.
29. Wulfken LM, Moritz R, Ohlmann C etal. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS ONE 2011; 6: e25787.
30. Gee HE, Buffa FM, Camps C etal. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br. J. Cancer 2011; 104: 1168-77.
31. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008; 14: 844-52.
32. Zaman MS, Shahryari V, Deng G etal. Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS ONE 2012; 7: e31060.
33. Juan D, Alexe G, Antes T etal. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010; 75: 835-41.
34. Dyrskjot L, Ostenfeld MS, Bramsen JB etal. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009; 69: 4851-60.
35. Fischer N, Goke F, Splittstosser V, Lankat-Buttgereit B, Muller SC, Ellinger J. Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma. Biochem. Biophys. Res. Commun. 2012; 417: 29-34.
36. Zhang HL, Yang LF, Zhu Y etal. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71: 326-31.
37. Kurashige J, Kamohara H, Watanabe M etal. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J. Surg. Oncol. 2012; doi: 10.1002/jso.23064.
38. Liu XG, Zhu WY, Huang YY etal. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 2012; 29: 618-26.
39. Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V, Pantel K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res. Treat. 2012; doi: 10.1007/s10549-012-1988-6.
40. Kong X, Du Y, Wang G etal. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig. Dis. Sci. 2011; 56: 602-9.
41. Liu R, Chen X, Du Y etal. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 2012; 58: 610-18.
42. Fang C, Zhu DX, Dong HJ etal. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann. Hematol. 2012; 91: 553-9.
43. Komatsu S, Ichikawa D, Takeshita H etal. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br. J. Cancer 2011; 105: 104-11.
44. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE 2011; 6: e28486.
45. Bihrer V, Waidmann O, Friedrich-Rust M etal. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS ONE 2011; 6: e26971.
46. Xu J, Wu C, Che X etal. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 2011; 50: 136-42.